skip to main content
Language:
Primo Advanced Search
Primo Advanced Search Query Term
Primo Advanced Search Query Term
Primo Advanced Search Query Term
Primo Advanced Search prefilters
Simple Search
Results 1 2 3 4 next page
Refined by: resource type: Newspaper Articles remove
Result Number Material Type Add to My Shelf Action Record Details and Options
1
Alkermes Presents Analyses From Long-Term Safety Study of LYBALVI (olanzapine and samidorphan) at 2024 Congress of the Schizophrenia International Research Society
Alkermes Presents Analyses From Long-Term Safety Study of LYBALVI (olanzapine and samidorphan) at 2024 Congress of the Schizophrenia International Research Society
Material Type:
Newspaper Article 		Add to e-Shelf

Alkermes Presents Analyses From Long-Term Safety Study of LYBALVI (olanzapine and samidorphan) at 2024 Congress of the Schizophrenia International Research Society

PR newswire, 2024-04-08

PR Newswire Association LLC

No full-text

Citations Cited by
2
Response Pharmaceuticals Announces Successful Completion of Phase 1B Clinical Trial for RDX-002, a Novel Small Molecule for the Treatment of Antipsychotic-Induced Weight Gain
Response Pharmaceuticals Announces Successful Completion of Phase 1B Clinical Trial for RDX-002, a Novel Small Molecule for the Treatment of Antipsychotic-Induced Weight Gain
Material Type:
Newspaper Article 		Add to e-Shelf

Response Pharmaceuticals Announces Successful Completion of Phase 1B Clinical Trial for RDX-002, a Novel Small Molecule for the Treatment of Antipsychotic-Induced Weight Gain

PR newswire, 2023-08-17

PR Newswire Association LLC

No full-text

Citations Cited by
3
Alkermes Announces Commercial Availability of LYBALVI for the Treatment of Schizophrenia and Bipolar I Disorder
Alkermes Announces Commercial Availability of LYBALVI for the Treatment of Schizophrenia and Bipolar I Disorder
Material Type:
Newspaper Article 		Add to e-Shelf

Alkermes Announces Commercial Availability of LYBALVI for the Treatment of Schizophrenia and Bipolar I Disorder

PR newswire, 2021-10-18

PR Newswire Association LLC

No full-text

Citations Cited by
4
Alkermes Announces FDA Approval of LYBALVI(TM) for the Treatment of Schizophrenia and Bipolar I Disorder
Alkermes Announces FDA Approval of LYBALVI(TM) for the Treatment of Schizophrenia and Bipolar I Disorder
Material Type:
Newspaper Article 		Add to e-Shelf

Alkermes Announces FDA Approval of LYBALVI(TM) for the Treatment of Schizophrenia and Bipolar I Disorder

PR newswire, 2021-06-01

PR Newswire Association LLC

No full-text

Citations Cited by
5
Prasco Selected as Eli Lilly and Company's Authorized Generics Partner
Prasco Selected as Eli Lilly and Company's Authorized Generics Partner
Material Type:
Newspaper Article 		Add to e-Shelf

Prasco Selected as Eli Lilly and Company's Authorized Generics Partner

PR newswire, 2011-10-20

PR Newswire Association LLC

No full-text

Citations Cited by
6
Impel Neuropharma to Present Data at 2019 American Psychiatric Association (APA) Annual Meeting
Impel Neuropharma to Present Data at 2019 American Psychiatric Association (APA) Annual Meeting
Material Type:
Newspaper Article 		Add to e-Shelf

Impel Neuropharma to Present Data at 2019 American Psychiatric Association (APA) Annual Meeting

PR newswire, 2019-05-17

PR Newswire Association LLC

No full-text

Citations Cited by
7
Alkermes Announces Positive Topline Results From ENLIGHTEN-Early Phase 3b Study of LYBALVI in Patients Early in Illness
Alkermes Announces Positive Topline Results From ENLIGHTEN-Early Phase 3b Study of LYBALVI in Patients Early in Illness
Material Type:
Newspaper Article 		Add to e-Shelf

Alkermes Announces Positive Topline Results From ENLIGHTEN-Early Phase 3b Study of LYBALVI in Patients Early in Illness

PR newswire, 2022-02-08

PR Newswire Association LLC

No full-text

Citations Cited by
8
FDA-APPROVED SCHIZOPHRENIA AND BIPOLAR I DISORDER TREATMENT INCLUDES COMPOUND DISCOVERED AT RENSSELAER
FDA-APPROVED SCHIZOPHRENIA AND BIPOLAR I DISORDER TREATMENT INCLUDES COMPOUND DISCOVERED AT RENSSELAER
Material Type:
Newspaper Article 		Add to e-Shelf

FDA-APPROVED SCHIZOPHRENIA AND BIPOLAR I DISORDER TREATMENT INCLUDES COMPOUND DISCOVERED AT RENSSELAER

States News Service, 2021-06-15

States News Service

No full-text

Citations Cited by
9
Starton Therapeutics and Haisco Pharmaceutical Announce an Exclusive Licensing Agreement to Develop and Commercialize STAR-OLZ for Nausea and Vomiting in China
Starton Therapeutics and Haisco Pharmaceutical Announce an Exclusive Licensing Agreement to Develop and Commercialize STAR-OLZ for Nausea and Vomiting in China
Material Type:
Newspaper Article 		Add to e-Shelf

Starton Therapeutics and Haisco Pharmaceutical Announce an Exclusive Licensing Agreement to Develop and Commercialize STAR-OLZ for Nausea and Vomiting in China

Marketwired, 2021-03-01

Marketwire L.P., by its general partner Marketwire Canada Limited

No full-text

Citations Cited by
10
Alkermes Announces Topline Results From Long-Term, Open-Label Safety and Durability of Treatment Effect Study of LYBALVI (olanzapine and samidorphan)
Alkermes Announces Topline Results From Long-Term, Open-Label Safety and Durability of Treatment Effect Study of LYBALVI (olanzapine and samidorphan)
Material Type:
Newspaper Article 		Add to e-Shelf

Alkermes Announces Topline Results From Long-Term, Open-Label Safety and Durability of Treatment Effect Study of LYBALVI (olanzapine and samidorphan)

PR newswire, 2024-01-03

PR Newswire Association LLC

No full-text

Citations Cited by
Results 1 2 3 4 next page

  • Implemented by: ABCD-USP USP   Social Network Logos: Freepik

Searching Remote Databases, Please Wait

  • Searching for
  • inscope:(USP_VIDEOS),scope:("PRIMO"),scope:(USP_FISICO),scope:(USP_EREVISTAS),scope:(USP),scope:(USP_EBOOKS),scope:(USP_PRODUCAO),primo_central_multiple_fe
  • Show me what you have so far